Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs.

Cells - 16 Jun 2021

Leonetti Alessandro, Capula Mjriam, Minari Roberta, Mazzaschi Giulia, Gregori Alessandro, El Hassouni Btissame, Papini Filippo, Bordi Paola, Verzè Michela, Avan Amir, Tiseo Marcello, Giovannetti Elisa

Abstract excerpt

BACKGROUND: Resistance to EGFR-TKIs constitutes a major challenge for the management of EGFR-mutated NSCLC, and recent evidence suggests that deregulation of specific microRNAs (miRNAs) may influence resistance to targeted agents. In this retrospective study, we explored the role of specific plasmatic miRNAs (miR-21, miR-27a and miR-181a) as a surrogate for predicting EGFR-TKI performance in EGFR-mutated NSCLC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to MicroRNAs

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 34208765
DOI: 10.3390/cells10061520
PMCID: PMC8235748

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs.PMID 34208765Read ↗

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutationSemantic proximity Read ↗

MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers.Semantic proximity Read ↗

microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.Semantic proximity Read ↗

Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.Semantic proximity Read ↗

Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patientsSemantic proximity Read ↗

Plasma MicroRNA-21 Concentration May Be a Useful Biomarker in Glioblastoma PatientsSemantic proximity Read ↗

[Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].Semantic proximity Read ↗

Relevance of circulating MiRNA-21 and MiRNA-181 in prediction of glioblastoma multiforme prognosisSemantic proximity Read ↗

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.Semantic proximity Read ↗

Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.Semantic proximity Read ↗

MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cellsSemantic proximity Read ↗

Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.